Abstract
Background: We previously reported that Resolvin E3(RvE3) dampens allergic airway inflammation in murine asthma model and suppresses the interleukin 23 pathway on bone marrow-derived dendritic cells(BMDCs). Though whether the efficacy of RvE3 is comparable to that of Resolvin E1(RvE1) is still unknown.
Aims and Objects: We determined the effect of RvE1 and RvE3 on allergic airway inflammation using a murine model of asthma and BMDCs.
Methods: In vivo, allergic airway inflammation was induced in BALB/c mice by House dust mite (HDM) sensitization and challenge (Day0-2,14-17) and RvE1 or RvE3 was administrated intraperitoneally after the last HDM challenge(Day17,18), and sacrificed on day 19. In vitro, BMDCs obtained from HDM-sensitized mice were stimulated with IL-33 and IL-4, then treated with RvE1 or RvE3 (10nM).
Results: In vivo, both RvE1 and RvE3 treatment significantly decreased the number of total inflammatory cell and eosinophil in BAL fluid and the difference of efficacy between RvE1 and RvE3 were not significant. In vitro, both RvE1 and RvE3 treatment suppressed the IL-23 release from IL-33/IL-4 stimulated BMDCs.
Conclusion: The efficacy of RvE3 on allergic airway inflammation is comparable to that of RvE1.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3299.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020
